CONCORDBIO2023-04-012023-06-30 CONCORDBIO2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member CONCORDBIO2023-06-30 CONCORDBIO2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member CONCORDBIO2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543960 CONCORDBIO NA Concord Biotech Limited Equity 2023-04-01 2024-03-31 2023-09-06 2023-08-29 INR Lakhs First quarter 14:30:00 15:30:00 2023-09-06 2023-09-06 Not applicable Single segment Pharmaceuticals 2023-04-01 2023-06-30 Unaudited Consolidated 1948277000.00 66545000.00 2014822000.00 394758000.00 115954000.00 -106726000.00 282541000.00 7532000.00 130412000.00 540229000.00 1364700000.00 650122000.00 0.00 650122000.00 163000000.00 2419000.00 165419000.00 0.00 484703000.00 0.00 0.00 0.00 60240000.00 544943000.00 -779000.00 544164000.00 544943000.00 0.00 -779000.00 0.00 104616000.00 1 5.21 5.21 0.00 0.00 5.21 5.21 1. The Company's equity shares are listed on National Stock Exchange ( NSE ) and on BSE Limited ( BSE ) on August 18, 2023 by completing Initial Public Offering through offer of sale of 2,09,25,652 equity shares of face value of Rs. 1 each at an issue price of Rs 741 per equity share by selling shareholder. Accordingly, the consolidated unaudited financial results of the Company for the quarter ended June 30, 2023 are drawn up for the first time in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. The above consolidated unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on September 6, 2023. 3. The Company and its joint venture are engaged in the business of manufacturing and trading in pharmaceutical products, which in the context of Indian Accounting Standard (Ind AS) 108- Operating Segment , is considered as the single operating segment. 4. The consolidated financial results for the quarter ended March 31, 2023 and June 30, 2022 have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the financial results for these periods provide a true and fair view of the Company's affairs. Other Expenses 540229000.00 Re-measurement gain/ (loss) on defined benefit plans -1041000.00 Income tax relating to Re-measurement gain/ (loss) on defined benefit plans 262000.00 -779000.00 0.00 0.00